Mobile

A facilitated access open-label, non-randomized, multicenter, long-term safety and efficacy study in Chronic Kidney Disease patients treated with SBR759 who have completed previous SBR759 studies

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-011007-23

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate long term safety data in patients who have completed a clinical study on SBR759 (ie: to provide long term safety and efficacy data on patients who have been titrated to achieve phosphate target within Phase II/III studies of SBR759 and completed these studies on SBR759. In addition, the study will provide access to continued SBR759 maintenance therapy for these patients. The study is an open-label, non-randomized design where patients will continue on their currently assigned dose from the previous SBR759 study)

Critère d'inclusion

  • hyperphosphataemia in patients with chronic kidney disease (CKD) on haemodialysis

Liens